FDA Approves Breztri for Asthma Patients 12+
The single-inhaler therapy Breztri Aerosphere is now indicated for maintenance treatment in adults and pediatric patients who remain symptomatic on dual therapies.
The single-inhaler therapy Breztri Aerosphere is now indicated for maintenance treatment in adults and pediatric patients who remain symptomatic on dual therapies.
The single-inhaler therapy Breztri Aerosphere is now indicated for maintenance treatment in adults and pediatric patients who remain symptomatic on dual therapies.
Read MoreAstraZeneca’s Breztri Aerosphere demonstrated statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with other pharmacology.
Read MoreTwo Phase III trials in patients with uncontrolled asthma found Breztri Aerosphere met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function.
Read More